- Home
- VNOM vs COGT Comparison
VNOM vs COGT Comparison
Compare VNOM & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VNOM | COGT |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 6.5B |
| IPO Year | 2014 | 2018 |
Fundamental Metrics
Financial Performance| Metric | VNOM | COGT |
|---|---|---|
| Price | $36.85 | $39.17 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 13 |
| Target Price | ★ $53.36 | $30.17 |
| AVG Volume (30 Days) | 2.0M | ★ 2.4M |
| Earning Date | 02-23-2026 | 02-24-2026 |
| Dividend Yield | ★ 6.47% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.93 | N/A |
| Revenue | ★ $1,131,200,000.00 | N/A |
| Revenue This Year | $58.96 | N/A |
| Revenue Next Year | $27.71 | N/A |
| P/E Ratio | $19.16 | ★ N/A |
| Revenue Growth | ★ 42.38 | N/A |
| 52 Week Low | $34.71 | $3.72 |
| 52 Week High | $52.03 | $43.73 |
Technical Indicators
Market Signals| Indicator | VNOM | COGT |
|---|---|---|
| Relative Strength Index (RSI) | 43.55 | 60.74 |
| Support Level | $36.19 | $33.84 |
| Resistance Level | $38.92 | $36.88 |
| Average True Range (ATR) | 1.13 | 1.93 |
| MACD | -0.05 | 0.07 |
| Stochastic Oscillator | 33.57 | 75.53 |
Price Performance
Historical ComparisonAbout VNOM Viper Energy Inc.
Viper Energy Inc is focused on owning and acquiring mineral and royalty interests in oil and natural gas properties in the Permian Basin. The Permian Basin is known to have a number of zones of oil and natural gas-bearing rock throughout.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.